miR‑592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin‑dependent kinase 8.


Journal

Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 19 08 2019
accepted: 25 03 2020
pubmed: 19 9 2020
medline: 1 5 2021
entrez: 18 9 2020
Statut: ppublish

Résumé

Medullary thyroid carcinoma (MTC) is a relatively rare subtype of thyroid cancer, accounting for 5‑10% of all cases of thyroid cancer worldwide. Due to the current lack of knowledge regarding the tumorigenesis of MTC, the clinical treatment of MTC remains a challenge. It has been reported that microRNAs (miRNAs) regulate the progression of MTC; however, the regulatory network of miRNAs and the exact underlying mechanisms are not completely understood. In the present study, an miRNA expression profile (GSE40807), consisting of 80 samples, was downloaded and analyzed using Gene Expression Omnibus‑2R to identify differentially expressed miRNAs between MTC and normal samples. miR‑592 expression levels were significantly increased in MTC tissues and cell lines compared with normal tissues and cell lines. Patients with high miR‑592 expression levels exhibited a less favorable prognosis compared with patients with low miR‑592 expression. The results suggested that miR‑592 overexpression promoted TT and MZ‑CRC‑1 cell proliferation in vitro. In addition, miR‑592 negatively regulated cyclin‑dependent kinase 8 (CDK8) via targeted binding in MTC cells. Moreover, co‑transfection of CDK8 overexpression plasmid and miR‑592 mimic reversed miR‑592‑mediated MTC cell proliferation. In conclusion, miR‑592 may serve as an oncogene in MTC by decreasing the expression of CDK8, indicating that the miR‑592/CDK8 axis might serve as a promising therapeutic target for MTC.

Identifiants

pubmed: 32945439
doi: 10.3892/mmr.2020.11392
pmc: PMC7453674
doi:

Substances chimiques

3' Untranslated Regions 0
MIRN592 microRNA, human 0
MicroRNAs 0
CDK8 protein, human EC 2.7.11.22
Cyclin-Dependent Kinase 8 EC 2.7.11.22

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3316-3326

Commentaires et corrections

Type : ErratumIn

Références

Front Oncol. 2019 Dec 06;9:1306
pubmed: 31867269
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595
pubmed: 30321428
J Cell Biochem. 2019 Nov;120(11):18927-18936
pubmed: 31245877
Oncotarget. 2017 Feb 21;8(8):12558-12575
pubmed: 28147342
Cancer. 2006 Nov 1;107(9):2134-42
pubmed: 17019736
Exp Mol Pathol. 2017 Oct;103(2):229-236
pubmed: 29107050
Am J Cancer Res. 2019 Jun 01;9(6):1118-1126
pubmed: 31285946
J Endocrinol Invest. 2018 Oct;41(10):1165-1172
pubmed: 29441462
Endocr Relat Cancer. 2019 Aug 1;26(9):R499-R518
pubmed: 31252403
Exp Mol Pathol. 2013 Aug;95(1):62-7
pubmed: 23685355
Mol Med Rep. 2019 Dec;20(6):5272-5278
pubmed: 31638208
Org Biomol Chem. 2015 Feb 28;13(8):2226-38
pubmed: 25574760
Gene. 2019 May 25;698:9-18
pubmed: 30825595
Methods Mol Biol. 2017;1617:261-280
pubmed: 28540691
Clin Endocrinol (Oxf). 2010 Apr;72(4):534-42
pubmed: 19563448
Tumour Biol. 2014 Sep;35(9):9343-53
pubmed: 24943685
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019 Jul 7;54(7):506-509
pubmed: 31315357
Oncol Rep. 2017 Dec;38(6):3447-3454
pubmed: 29039599
BMC Cancer. 2019 Nov 12;19(1):1093
pubmed: 31718618
J Allergy Clin Immunol. 2018 Apr;141(4):1202-1207
pubmed: 29074454
Clin Cancer Res. 2017 Apr 1;23(7):1829-1840
pubmed: 27678455
J Med Chem. 2018 Jun 28;61(12):5073-5092
pubmed: 29266937
Int J Mol Sci. 2016 Oct 13;17(10):
pubmed: 27754357
J Thyroid Res. 2019 Jul 7;2019:1893047
pubmed: 31360432
Semin Liver Dis. 2015 Feb;35(1):3-11
pubmed: 25632930
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Cancer Cytopathol. 2016 Jan;124(1):14-27
pubmed: 26348024
J Clin Endocrinol Metab. 2008 May;93(5):1600-8
pubmed: 18270258
Methods Mol Biol. 2016;1418:93-110
pubmed: 27008011
Sci Rep. 2018 Oct 31;8(1):16138
pubmed: 30382159
Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1610-1619
pubmed: 30840284
Biomed Pharmacother. 2015 Feb;69:214-20
pubmed: 25661360
Am J Cancer Res. 2018 Jun 01;8(6):1030-1039
pubmed: 30034940
J Am Coll Surg. 2005 Jun;200(6):890-6
pubmed: 15922202
J Cell Biochem. 2019 Aug;120(8):14095-14106
pubmed: 31087707
Clin Cancer Res. 2011 Jul 15;17(14):4772-81
pubmed: 21622722
Exp Cell Res. 2018 Aug 15;369(2):304-315
pubmed: 29856990
Int J Clin Exp Med. 2015 Sep 15;8(9):15246-53
pubmed: 26629010
J Exp Clin Cancer Res. 2018 Nov 21;37(1):279
pubmed: 30463570
Oncotarget. 2017 Feb 28;8(9):14269-14270
pubmed: 28209918
Oncotarget. 2016 Aug 9;7(32):52475-52492
pubmed: 27248468
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
Endocrine. 2019 Sep;65(3):582-594
pubmed: 30927143
Expert Opin Ther Targets. 2016 Jul;20(7):771-82
pubmed: 27167185
Cell Death Dis. 2019 Feb 27;10(3):195
pubmed: 30814512
Oncoimmunology. 2017 Nov 9;7(2):e1387705
pubmed: 29308313
Apoptosis. 2018 Apr;23(3-4):237-250
pubmed: 29516317
Lancet. 2016 Dec 3;388(10061):2783-2795
pubmed: 27240885
Mol Ther Oncolytics. 2019 Nov 13;15:248-260
pubmed: 31890869
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
Neuroreport. 2018 Nov 7;29(16):1391-1399
pubmed: 30169426
Cell Physiol Biochem. 2018;47(4):1465-1481
pubmed: 29949784
Endocr Pathol. 2016 Dec;27(4):312-324
pubmed: 27539727
Oncotarget. 2019 Jan 18;10(6):622-623
pubmed: 30774756
JAMA Surg. 2018 Jan 1;153(1):52-59
pubmed: 28973144
Cancers (Basel). 2019 Jun 27;11(7):
pubmed: 31252590

Auteurs

Ting Liu (T)

Department of Nuclear Medicine, The Affiliated Wuhan Central Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China.

Jingjing Meng (J)

Department of Thyroid and Breast Surgery, The Affiliated Wuhan Central Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China.

Yu Zhang (Y)

Department of Surgery II, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH